Risk factors for disease generalization in acetylcholine receptor antibody-positive ocular myasthenia: a multicenter retrospective study - Report - MDSpire
Advertisement
Risk factors for disease generalization in acetylcholine receptor antibody-positive ocular myasthenia: a multicenter retrospective study
Clinical Report: Identifying Risk Factors for Disease Progression in Ocular Myasthenia Gravis
Overview
This multicenter retrospective analysis identifies factors associated with secondary generalization in patients with ocular-onset myasthenia gravis (OoMG) who are positive for anti-acetylcholine receptor (AChR) antibodies. Key findings indicate that higher anti-AChR antibody titers and abnormal facial repetitive nerve stimulation are linked to an increased risk of progression to generalized myasthenia gravis (gMG).
Background
Ocular myasthenia gravis (OoMG) is a chronic autoimmune neuromuscular disorder that can progress to generalized myasthenia gravis (gMG), impacting patient quality of life and treatment strategies. Identifying reliable predictors of disease progression is crucial for early risk stratification and optimizing therapeutic interventions. This study focuses on patients with anti-AChR antibodies, which are prevalent in myasthenia gravis cases.
Data Highlights
Parameter
Value
Patients with gMG
40 (47.1%)
HR for anti-AChR antibody titers
3.37 (95% CI 1.53–7.43; p = 0.002)
HR for abnormal RNS
2.49 (95% CI 1.16–5.34; p = 0.020)
Key Findings
47.1% of patients with anti-AChR-positive OoMG developed gMG during follow-up.
Higher anti-AChR antibody titers were significantly associated with secondary generalization.
Abnormal repetitive nerve stimulation of facial muscles was linked to increased risk of progression.
No independent predictors were identified in multivariable analysis.
Combined assessment of identified factors may aid in early clinical risk stratification.
Clinical Implications
Clinicians should monitor anti-AChR antibody titers and perform repetitive nerve stimulation tests in patients with ocular myasthenia gravis to assess the risk of progression to generalized myasthenia gravis. Early identification of at-risk patients can guide therapeutic decision-making and improve long-term outcomes.
Conclusion
The study highlights the importance of specific clinical and laboratory factors in predicting disease progression in ocular myasthenia gravis. Further research is needed to validate these findings and enhance prognostic assessments.
by Lorenzo Verriello, Roberto Sartor, Fabrizio Bellizzi, Chiara Dalla Torre, Maria Elena Pessa, Marco Belluzzo, Alessio Bratina, Magda Quagliotto, Chiara Rosa Mancinelli, Michele Rana, Fulvio Pasquin, Martina Fabris, Giada Pauletto, Miriam Isola, Maria De Martino, Paolo Manganotti, Mariarosaria Valente
